Li Hui, Du Shiyu, Niu Panpan, Gu Xiaosong, Wang Jun, Zhao Ying
Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Department of Pathophysiology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China.
Front Pharmacol. 2021 Jul 8;12:679707. doi: 10.3389/fphar.2021.679707. eCollection 2021.
Vascular adhesion protein-1 (VAP-1) is a semicarbazide-sensitive amine oxidase (SSAO), whose enzymatic activity regulates the adhesion/exudation of leukocytes in/from blood vessels. Due to its abundant expressions in vascular systems and prominent roles in inflammations, increasing attentions have been paid to the roles of VAP-1/SSAO in atherosclerosis, a chronic vascular inflammation that eventually drives clinical cardiovascular events. Clinical studies have demonstrated a potential value of soluble VAP-1 (sVAP-1) for the diagnosis and prognosis of cardiovascular diseases. Recent findings revealed that VAP-1 is expressed in atherosclerotic plaques and treatment with VAP-1 inhibitors alleviates the progression of atherosclerosis. This review will focus on the roles of VAP-1/SSAO in the progression of atherosclerotic lesions and therapeutic potentials of VAP-1 inhibitors for cardiovascular diseases.
血管黏附蛋白-1(VAP-1)是一种氨基脲敏感性胺氧化酶(SSAO),其酶活性调节白细胞在血管内的黏附/渗出或从血管中的黏附/渗出。由于其在血管系统中的丰富表达以及在炎症中的突出作用,VAP-1/SSAO在动脉粥样硬化(一种最终导致临床心血管事件的慢性血管炎症)中的作用受到了越来越多的关注。临床研究表明可溶性VAP-1(sVAP-1)在心血管疾病的诊断和预后方面具有潜在价值。最近的研究结果显示VAP-1在动脉粥样硬化斑块中表达,用VAP-1抑制剂治疗可减轻动脉粥样硬化的进展。本综述将聚焦于VAP-1/SSAO在动脉粥样硬化病变进展中的作用以及VAP-1抑制剂在心血管疾病治疗方面的潜力。